EVOKE PHARMA, INC.: 10-K/A filed 2024-05-14

Name: EVOKE PHARMA, INC.: 10-K/A filed 2024-05-14
Creator: EVOKE PHARMA, INC.

What EVOKE PHARMA, INC. reported in its annual report amendment filed 2024-05-14 (fiscal FY 2023): 29 published measures, 80 facts as tagged in accession 0000950170-24-059516.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form: 10-K/A (annual report amendment)
Filed: 2024-05-14
Fiscal period: fiscal FY 2023
Accession: 0000950170-24-059516 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All EVOKE PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit
At 2023-12-31	7,068,546	USD
At 2023-09-30	7,852,974	USD
At 2023-06-30	8,979,697	USD
At 2022-12-31	11,851,488	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit
At 2023-12-31	9,648,083	USD
At 2023-09-30	8,726,749	USD
At 2023-06-30	8,441,323	USD
At 2022-12-31	7,766,839	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-12-31	-2,579,537	USD
At 2023-09-30	-873,775	USD
At 2023-06-30	538,374	USD
At 2023-03-31	2,100,000	USD
At 2022-12-31	4,084,649	USD
At 2021-12-31	3,555,094	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2023-12-31	4,739,426	USD
At 2023-09-30	5,964,826	USD
At 2023-06-30	7,006,431	USD
At 2022-12-31	9,843,699	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-7,792,295	USD	365
2022-01-01 to 2022-12-31	-8,224,130	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-4,984,977	USD	365
2022-01-01 to 2022-12-31	-6,595,987	USD	365

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	5,180,630	USD	365
2022-01-01 to 2022-12-31	2,508,645	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-119,296	USD	365
2022-01-01 to 2022-12-31	7,294,976	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit
At 2023-12-31	-123,439,438	USD
At 2023-09-30	-121,452,037	USD
At 2023-06-30	-119,758,130	USD
At 2022-12-31	-115,647,143	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	3,343,070	shares	365
2022-01-01 to 2022-12-31	3,143,626	shares	365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	3,343,070	shares	365
2022-01-01 to 2022-12-31	3,143,626	shares	365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-2.33	USD/shares	365
2022-01-01 to 2022-12-31	-2.62	USD/shares	365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-2.33	USD/shares	365
2022-01-01 to 2022-12-31	-2.62	USD/shares	365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	1,128,109	USD	365
2022-01-01 to 2022-12-31	1,458,709	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-7,430,891	USD	365
2022-01-01 to 2022-12-31	-7,786,137	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit
At 2023-12-31	6,826,909	USD
At 2023-09-30	7,839,604	USD
At 2023-06-30	8,926,855	USD
At 2022-12-31	11,722,414	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	500,000	USD	365
2022-01-01 to 2022-12-31	500,000	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit
At 2023-12-31	9,648,083	USD
At 2023-09-30	8,726,749	USD
At 2023-06-30	8,441,323	USD
At 2022-12-31	1,654,544	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2023-09-30	1,233,904	USD
At 2023-06-30	1,023,813	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	12,611,521	USD	365
2022-01-01 to 2022-12-31	10,294,782	USD	365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit
At 2023-12-31	481,840	USD
At 2023-09-30	504,925	USD
At 2023-06-30	513,712	USD
At 2022-12-31	289,378	USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	12,227,735	USD	365
2022-01-01 to 2022-12-31	9,623,599	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit
At 2023-12-31	3,343,070	shares
At 2023-09-30	3,343,070	shares
At 2023-06-30	3,343,070	shares
At 2022-12-31	3,343,070	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-12-31	4,739,426	USD
At 2022-12-31	9,843,699	USD
At 2021-12-31	9,144,710	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit
At 2023-09-30	13,370	USD
At 2023-06-30	52,842	USD
At 2022-12-31	129,074	USD

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	-361,404	USD	365
2022-01-01 to 2022-12-31	-437,993	USD	365

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	146,000	USD	365
2022-01-01 to 2022-12-31	39,000	USD	365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	48,239	USD	365
2022-01-01 to 2022-12-31	329,639	USD	365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-12-31	192,462	USD	365
2022-01-01 to 2022-12-31	103,843	USD	365

Inspect the source

Entity: EVOKE PHARMA, INC. / CIK 0001403708
Captured: 2026-09-21T17:19:23.305Z
SEC response SHA-256: 1d2ea0edbbb48066d62d49983dacdd25cf55cdf81e3ee5a742e26303a1f7d06e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001403708.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))